JP2017537083A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537083A5 JP2017537083A5 JP2017525408A JP2017525408A JP2017537083A5 JP 2017537083 A5 JP2017537083 A5 JP 2017537083A5 JP 2017525408 A JP2017525408 A JP 2017525408A JP 2017525408 A JP2017525408 A JP 2017525408A JP 2017537083 A5 JP2017537083 A5 JP 2017537083A5
- Authority
- JP
- Japan
- Prior art keywords
- melatonin
- subject
- level
- pharmaceutical composition
- agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims description 74
- 229960003987 melatonin Drugs 0.000 claims description 74
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims description 74
- 201000006417 multiple sclerosis Diseases 0.000 claims description 47
- 239000000556 agonist Substances 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 29
- 230000006866 deterioration Effects 0.000 claims description 21
- 230000001932 seasonal effect Effects 0.000 claims description 21
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 16
- YLXDSYKOBKBWJQ-LBPRGKRZSA-N N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e]benzofuran-8-yl]ethyl]propanamide Chemical group C1=C2OCCC2=C2[C@H](CCNC(=O)CC)CCC2=C1 YLXDSYKOBKBWJQ-LBPRGKRZSA-N 0.000 claims description 16
- RKHCTAKUYDTFHE-QMMMGPOBSA-N ly-156,735 Chemical compound C1=C(Cl)C(OC)=CC2=C1NC=C2[C@@H](C)CNC(C)=O RKHCTAKUYDTFHE-QMMMGPOBSA-N 0.000 claims description 16
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 12
- QQEILXDLZRLTME-UHFFFAOYSA-N 6-sulfatoxymelatonin Chemical compound C1=C(OS(O)(=O)=O)C(OC)=CC2=C1NC=C2CCNC(C)=O QQEILXDLZRLTME-UHFFFAOYSA-N 0.000 claims description 8
- YJYPHIXNFHFHND-UHFFFAOYSA-N agomelatine Chemical compound C1=CC=C(CCNC(C)=O)C2=CC(OC)=CC=C21 YJYPHIXNFHFHND-UHFFFAOYSA-N 0.000 claims description 8
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- 229960001150 ramelteon Drugs 0.000 claims description 8
- PTOIAAWZLUQTIO-GXFFZTMASA-N tasimelteon Chemical compound CCC(=O)NC[C@@H]1C[C@H]1C1=CC=CC2=C1CCO2 PTOIAAWZLUQTIO-GXFFZTMASA-N 0.000 claims description 8
- 229960000660 tasimelteon Drugs 0.000 claims description 8
- 229940109239 creatinine Drugs 0.000 claims description 6
- PTOIAAWZLUQTIO-UHFFFAOYSA-N n-[[2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl]propanamide Chemical compound CCC(=O)NCC1CC1C1=CC=CC2=C1CCO2 PTOIAAWZLUQTIO-UHFFFAOYSA-N 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 210000000068 Th17 cell Anatomy 0.000 claims description 2
- 206010047642 Vitiligo Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 238000007913 intrathecal administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 210000003289 regulatory T cell Anatomy 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000005671 spondyloarthropathy Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 125000004565 2,3-dihydrobenzofuran-4-yl group Chemical group O1CCC2=C1C=CC=C2* 0.000 claims 2
- -1 6- chloro-5-methoxy -1H- indol-3-yl Chemical group 0.000 claims 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 2
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 2
- 239000005557 antagonist Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462078473P | 2014-11-12 | 2014-11-12 | |
| US62/078,473 | 2014-11-12 | ||
| PCT/US2015/060488 WO2016077654A1 (en) | 2014-11-12 | 2015-11-12 | Melatonin in autoimmune disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017537083A JP2017537083A (ja) | 2017-12-14 |
| JP2017537083A5 true JP2017537083A5 (https=) | 2018-12-20 |
Family
ID=55955090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525408A Pending JP2017537083A (ja) | 2014-11-12 | 2015-11-12 | 自己免疫疾患におけるメラトニン |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10555919B2 (https=) |
| EP (1) | EP3217973A4 (https=) |
| JP (1) | JP2017537083A (https=) |
| CN (1) | CN107106543A (https=) |
| CA (1) | CA2967961A1 (https=) |
| WO (1) | WO2016077654A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10613874B2 (en) * | 2015-08-31 | 2020-04-07 | Mitsubishi Electric Corporation | Application execution apparatus and application execution method |
| JP2021515037A (ja) | 2018-02-26 | 2021-06-17 | アントルクス，インコーポレーテッド | 寛容原性リポソーム及びその使用方法 |
| RU2693050C1 (ru) * | 2018-09-11 | 2019-07-01 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта" | Способ лечения наружного генитального эндометриоза |
| CN114907333B (zh) * | 2022-05-11 | 2023-07-04 | 中国人民解放军军事科学院军事医学研究院 | 环丙甲酰胺衍生物及其制备方法和用途 |
| CN115282151B (zh) * | 2022-08-23 | 2023-06-09 | 黑龙江护理高等专科学校 | 一种拉米替隆的应用 |
| CN116712441B (zh) * | 2023-07-24 | 2024-04-05 | 南开大学 | 一种天然产物在制备治疗自身免疫性疾病的药物中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020040018A1 (en) * | 2000-06-23 | 2002-04-04 | Jones Robert M. | Subtype selective melatonergics |
| US20060223877A1 (en) * | 2005-03-31 | 2006-10-05 | Zemlan Frank P | Methods of treatment utilizing certain melatonin derivatives |
| US8389739B1 (en) | 2006-10-05 | 2013-03-05 | Orphagen Pharmaceuticals | Modulators of retinoid-related orphan receptor gamma |
| WO2008083204A2 (en) * | 2006-12-28 | 2008-07-10 | Braincells, Inc. | Modulation of neurogenesis by melatoninergic ligands |
| WO2013033310A1 (en) * | 2011-08-31 | 2013-03-07 | Theodore Mark Kamenecka | Modulators of rev-erb |
-
2015
- 2015-11-12 CN CN201580073200.2A patent/CN107106543A/zh active Pending
- 2015-11-12 EP EP15858738.6A patent/EP3217973A4/en not_active Withdrawn
- 2015-11-12 US US15/525,375 patent/US10555919B2/en active Active
- 2015-11-12 CA CA2967961A patent/CA2967961A1/en not_active Abandoned
- 2015-11-12 JP JP2017525408A patent/JP2017537083A/ja active Pending
- 2015-11-12 WO PCT/US2015/060488 patent/WO2016077654A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537083A5 (https=) | ||
| Brunet et al. | Trauma reactivation under the influence of propranolol decreases posttraumatic stress symptoms and disorder: 3 open-label trials | |
| van Paassen et al. | PMP22 related neuropathies: Charcot-Marie-Tooth disease type 1A and Hereditary Neuropathy with liability to Pressure Palsies | |
| Scanlon et al. | Epithelial anion transporter pendrin contributes to inflammatory lung pathology in mouse models of Bordetella pertussis infection | |
| JP2017534638A5 (https=) | ||
| JP2017528483A5 (https=) | ||
| JP2011184466A5 (https=) | ||
| Arnold et al. | Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study | |
| JP2019516739A5 (https=) | ||
| JP2016506933A5 (https=) | ||
| JP2013509441A5 (https=) | ||
| JP2019529541A5 (https=) | ||
| Choi et al. | Association of ABCB1 polymorphisms with the efficacy of ondansetron for postoperative nausea and vomiting | |
| Peng et al. | YY1 promotes microglia M2 polarization through the MIR-130A-3P/TREM-2 axis to alleviate sepsis-associated encephalopathy | |
| Varkal et al. | Pediatric Guillain-Barré syndrome: Indicators for a severe course | |
| Dang et al. | Transcriptional approach to study porcine tracheal epithelial cells individually or dually infected with swine influenza virus and Streptococcus suis | |
| Denker et al. | Use of continuous positive airway pressure for sleep apnea in the treatment of hypertension | |
| Yadegari et al. | Clinical and electrophysiological features of Guillain–Barré syndrome in Iran | |
| RU2020133768A (ru) | Способ лечения астмы или аллергического заболевания | |
| NZ621356A (en) | Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence | |
| JP2007521333A5 (https=) | ||
| Kamijima et al. | A placebo-controlled, randomized withdrawal study of sertraline for major depressive disorder in Japan | |
| Akpınar et al. | Agomelatine versus sertraline: an observational, open-labeled and 12 weeks follow-up study on efficacy and tolerability | |
| Merolla et al. | Micronized/ultramicronized palmitoylethanolamide improves depression and fatigue in coronavirus disease 2019 (COVID-19) survivors | |
| JP6528314B2 (ja) | Ａ（Ｈ１Ｎ１）ｐｄｍ０９インフルエンザウイルス感染による気管支喘息の予防又は改善剤 |